{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T15:10:04Z","timestamp":1719414604532},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,24]]},"DOI":"10.7759\/cureus.22575","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T01:21:16Z","timestamp":1645752076000},"source":"Crossref","is-referenced-by-count":3,"title":["Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer"],"prefix":"10.7759","author":[{"given":"Tejasvi","family":"Sunkara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Samyuktha","family":"Bandaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra","family":"Boyilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Kunadharaju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithvi","family":"Kukkadapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithya","family":"Chennamadhavuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel RL","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019, 69:7-34. 10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery MA","year":"2018","unstructured":"Lowery MA, Wong W, Jordan EJ, et al.. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst. 2018, 110:1067-74. 10.1093\/jnci\/djy024","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo K","year":"2017","unstructured":"Shindo K, Yu J, Suenaga M, et al.. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017, 35:3382-90. 10.1200\/JCO.2017.72.3502","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","author":"Yurgelun MB","year":"2019","unstructured":"Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al.. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019, 21:213-23. 10.1038\/s41436-018-0009-5","journal-title":"Genet Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.042","article-title":"Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer","volume":"148","author":"Grant RC","year":"2015","unstructured":"Grant RC, Selander I, Connor AA, et al.. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015, 148:556-64. 10.1053\/j.gastro.2014.11.042","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2 germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn SA","year":"2003","unstructured":"Hahn SA, Greenhalf B, Ellis I, et al.. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003, 95:214-21. 10.1093\/jnci\/95.3.214","journal-title":"J Natl Cancer Inst"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20855","article-title":"Genetic susceptibility to pancreatic cancer","volume":"51","author":"Klein AP","year":"2012","unstructured":"Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012, 51:14-24. 10.1002\/mc.20855","journal-title":"Mol Carcinog"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker D","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y, et al.. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017, 318:825-35. 10.1001\/jama.2017.11137","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter S","year":"2015","unstructured":"Holter S, Borgida A, Dodd A, et al.. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015, 33:3124-9. 10.1200\/JCO.2014.59.7401","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","unstructured":"Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91.1310-6. 10.1093\/jnci\/91.15.1310","journal-title":"J Natl Cancer Inst"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.028829","article-title":"Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","author":"van Asperen CJ","year":"2005","unstructured":"van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al.. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005, 42:711-9. 10.1136\/jmg.2004.028829","journal-title":"J Med Genet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.8.2.7136","article-title":"Absence of germline BRCA1 mutations in familial pancreatic cancer patients","volume":"8","author":"Axilbund JE","year":"2009","unstructured":"Axilbund JE, Argani P, Kamiyama M, et al.. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009, 8:131-5. 10.4161\/cbt.8.2.7136","journal-title":"Cancer Biol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-010-9414-x","article-title":"German national case collection for familial pancreatic cancer (FaPaCa): ten years experience","volume":"10","author":"Schneider R","year":"2011","unstructured":"Schneider R, Slater EP, Sina M, et al.. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer. 2011, 10:323-30. 10.1007\/s10689-010-9414-x","journal-title":"Fam Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-011-9426-1","article-title":"PALB2 mutations in familial breast and pancreatic cancer","volume":"10","author":"Hofstatter EW","year":"2011","unstructured":"Hofstatter EW, Domchek SM, Miron A, et al.. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011, 10:225-31. 10.1007\/s10689-011-9426-1","journal-title":"Fam Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0194","article-title":"ATM mutations in patients with hereditary pancreatic cancer","volume":"2","author":"Roberts NJ","year":"2012","unstructured":"Roberts NJ, Jiao Y, Yu J, et al.. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012, 2:41-6. 10.1158\/2159-8290.CD-11-0194","journal-title":"Cancer Discov"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients","volume":"25","author":"Hu C","year":"2016","unstructured":"Hu C, Hart SN, Bamlet WR, et al.. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev. 2016, 25:207-11. 10.1158\/1055-9965.EPI-15-0455","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200212000-00005","article-title":"CDKN2A germline mutations in familial pancreatic cancer","volume":"236","author":"Bartsch DK","year":"2002","unstructured":"Bartsch DK, Sina-Frey M, Lang S, et al.. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg. 2002, 236:730-7. 10.1097\/00000658-200212000-00005","journal-title":"Ann Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0403","article-title":"Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families","volume":"14","author":"de Snoo FA","year":"2008","unstructured":"de Snoo FA, Bishop DT, Bergman W, et al.. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008, 14:7151-7. 10.1158\/1078-0432.CCR-08-0403","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000915)87:6<809::AID-IJC8>3.0.CO;2-U","article-title":"Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden)","volume":"87","author":"Vasen HF","year":"2000","unstructured":"Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000, 87:809-11. 10.1002\/1097-0215(20000915)87:6&lt;809::AID-IJC8&gt;3.0.CO;2-U","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant HE","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, et al.. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005, 434:913-7. 10.1038\/nature03443","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer H","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al.. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005, 434:917-21. 10.1038\/nature03445","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2014.06.003","article-title":"Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches","volume":"30","author":"Dietlein F","year":"2014","unstructured":"Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014, 30:326-39. 10.1016\/j.tig.2014.06.003","journal-title":"Trends Genet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo J","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, et al.. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019, 30:1437-47. 10.1093\/annonc\/mdz192","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan T","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, et al.. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014, 111:1132-8. 10.1038\/bjc.2014.418","journal-title":"Br J Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al.. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017, 377:523-33. 10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore K","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al.. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018, 379:2495-505. 10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo J","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, et al.. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020, 21:162-74. 10.1016\/S1470-2045(19)30684-9","journal-title":"Lancet Oncol"},{"key":"ref29","unstructured":"Pancreatic adenocarcinoma. (2019). Accessed. February 6, 2022: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2015-1651","article-title":"Abstract 1651: BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models","volume":"75","author":"Tang Z","year":"2015","unstructured":"Tang Z, Jiang B, Shi Z, et al.. Abstract 1651: BGB-290, a novel PARP inhibitor with unique brain penetration ability, demonstrated strong synergism with temozolomide in subcutaneous and intracranial xenograft models. Cancer Res. 2015, 75:1651. 10.1158\/1538-7445.Am2015-1651","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai J","year":"2014","unstructured":"Murai J, Huang SY, Renaud A, et al.. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014, 13:433-43. 10.1158\/1535-7163.MCT-13-0803","journal-title":"Mol Cancer Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors","volume":"13","author":"Hopkins TA","year":"2015","unstructured":"Hopkins TA, Shi Y, Rodriguez LE, et al.. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015, 13:1465-77. 10.1158\/1541-7786.MCR-15-0191-T","journal-title":"Mol Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al.. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019, 381:317-27. 10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.297","article-title":"Phase II study of olaparib for BRCAness phenotype in pancreatic cancer","volume":"36","author":"Golan T","year":"2018","unstructured":"Golan T, Varadhachary GR, Sela T, et al.. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. J Clin Oncol. 2018, 36:297. 10.1200\/JCO.2018.36.4_suppl.297","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek SM","year":"2016","unstructured":"Domchek SM, Aghajanian C, Shapira-Frommer R, et al.. Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016, 140:199-203. 10.1016\/j.ygyno.2015.12.020","journal-title":"Gynecol Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu581","article-title":"Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer","volume":"26","author":"Bendell J","year":"2015","unstructured":"Bendell J, O'Reilly EM, Middleton MR, et al.. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced\/metastatic pancreatic cancer. Ann Oncol. 2015, 26:804-11. 10.1093\/annonc\/mdu581","journal-title":"Ann Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17237","article-title":"Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer","volume":"8","author":"Yarchoan M","year":"2017","unstructured":"Yarchoan M, Myzak MC, Johnson BA 3rd, et al.. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget. 2017, 8:44073-81. 10.18632\/oncotarget.17237","journal-title":"Oncotarget"},{"key":"ref38","unstructured":"Phase II trial of AZD6738 alone and in combination with olaparib. (2022). Accessed. February 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03682289."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13758","article-title":"Clinical activity and safety of cediranib and olaparib combination in patients with metastatic pancreatic ductal adenocarcinoma without BRCA mutation","volume":"26","author":"Kim JW","year":"2021","unstructured":"Kim JW, Cardin DB, Vaishampayan UN, et al.. Clinical activity and safety of cediranib and olaparib combination in patients with metastatic pancreatic ductal adenocarcinoma without BRCA mutation. Oncologist. 2021, 26:e1104-9. 10.1002\/onco.13758","journal-title":"Oncologist"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.3085","article-title":"First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed\/refractory (RR) malignant solid tumor and lymphoma: preliminary data","volume":"37","author":"Wang JS","year":"2019","unstructured":"Wang JS, Vita SD, Karlix JL, et al.. First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed\/refractory (RR) malignant solid tumor and lymphoma: preliminary data. J Clin Oncol. 2019, 37:3085. 10.1200\/JCO.2019.37.15_suppl.3085","journal-title":"J Clin Oncol"},{"key":"ref41","unstructured":"Targeted PARP or MEK\/ERK inhibition in patients with pancreatic cancer. (2019). Accessed. February 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04005690."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062016-050343","article-title":"Basket studies: redefining clinical trials in the era of genome-driven oncology","volume":"69","author":"Tao JJ","year":"2018","unstructured":"Tao JJ, Schram AM, Hyman DM. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu Rev Med. 2018, 69:319-31. 10.1146\/annurev-med-062016-050343","journal-title":"Annu Rev Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.26_suppl.135","article-title":"Outcome of BRCA 1\/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V)","volume":"32","author":"Pahuja S","year":"2014","unstructured":"Pahuja S, Beumer JH, Appleman LJ, et al.. Outcome of BRCA 1\/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V). J Clin Oncol. 2014, 32:135. 10.1200\/jco.2014.32.26_suppl.135","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.12.060","article-title":"A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer","volume":"40","author":"Tuli R","year":"2019","unstructured":"Tuli R, Shiao SL, Nissen N, et al.. A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019, 40:375-81. 10.1016\/j.ebiom.2018.12.060","journal-title":"EBioMedicine"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4015","article-title":"Final report of a phase I\/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC)","volume":"37","author":"Pishvaian MJ","year":"2019","unstructured":"Pishvaian MJ, Wang H, Parenti S, et al.. Final report of a phase I\/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). J Clin Oncol. 2019, 37:4015. 10.1200\/JCO.2019.37.15_suppl.4015","journal-title":"J Clin Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly EM","year":"2020","unstructured":"O'Reilly EM, Lee JW, Zalupski M, et al.. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol. 2020, 38:1378-88. 10.1200\/JCO.19.02931","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4014","article-title":"Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513","volume":"37","author":"Chiorean EG","year":"2019","unstructured":"Chiorean EG, Guthrie KA, Philip PA, et al.. Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. J Clin Oncol. 2019, 37:4014. 10.1200\/JCO.2019.37.15_suppl.4014","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.314","article-title":"A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors","volume":"36","author":"Turk AA","year":"2018","unstructured":"Turk AA, Deming DA, Lubner SJ, et al.. A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors. J Clin Oncol. 2018, 36:314. 10.1200\/JCO.2018.36.4_suppl.314","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0652","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors","volume":"22","author":"LoRusso PM","year":"2016","unstructured":"LoRusso PM, Li J, Burger A, et al.. Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. Clin Cancer Res. 2016, 22:3227-37. 10.1158\/1078-0432.CCR-15-0652","journal-title":"Clin Cancer Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2019-ct234","article-title":"Abstract CT234: a Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2","volume":"79","author":"Binder KA","year":"2019","unstructured":"Binder KA, Mick R, O'Hara M, et al.. Abstract CT234: a Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. Cancer Res. 2019, 79:234. 10.1158\/1538-7445.Am2019-ct234","journal-title":"Cancer Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff RT","year":"2018","unstructured":"Shroff RT, Hendifar A, McWilliams RR, et al.. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol. 2018, 2018:10.1200\/PO.17.00316","journal-title":"JCO Precis Oncol"},{"key":"ref52","unstructured":"Liposomal irinotecan, fluorouracil, leucovorin calcium, and rucaparib in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer. (2017). Accessed. February 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03337087."},{"key":"ref53","unstructured":"A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR). (2019). Accessed. February 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04171700."},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4071","article-title":"Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies","volume":"26","author":"Falchook G","year":"2020","unstructured":"Falchook G, Rosen S, LoRusso P, et al.. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin Cancer Res. 2020, 26:1247-57. 10.1158\/1078-0432.CCR-18-4071","journal-title":"Clin Cancer Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono J","year":"2017","unstructured":"de Bono J, Ramanathan RK, Mina L, et al.. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers. Cancer Discov. 2017, 7:620-9. 10.1158\/2159-8290.CD-16-1250","journal-title":"Cancer Discov"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1042\/BST20191092","article-title":"Systems approach to rational combination therapy: PARP inhibitors","volume":"48","author":"Sun C","year":"2020","unstructured":"Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans. 2020, 48:1101-8. 10.1042\/BST20191092","journal-title":"Biochem Soc Trans"},{"key":"ref57","unstructured":"Niraparib in patients with pancreatic cancer. (2018). Accessed. February 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03601923."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4168","article-title":"Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): a phase 2 trial","volume":"37","author":"Kasi A","year":"2019","unstructured":"Kasi A, Chalise P, Williamson SK, et al.. Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): a phase 2 trial. J Clin Oncol. 2019, 37:4168. 10.1200\/JCO.2019.37.15_suppl.TPS4168","journal-title":"J Clin Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4161","article-title":"A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy","volume":"37","author":"Reiss KA","year":"2019","unstructured":"Reiss KA, Mick R, O'Hara MH, et al.. A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy. J Clin Oncol. 2019, 37:4161. 10.1200\/JCO.2019.37.15_suppl.TPS4161","journal-title":"J Clin Oncol"},{"key":"ref60","unstructured":"Basket combination study of inhibitors of DNA damage response, angiogenesis and programmed death ligand 1 in patients with advanced solid tumors (DAPPER). (2019). Accessed. February 6, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03851614."},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord CJ","year":"2013","unstructured":"Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013, 19:1381-8. 10.1038\/nm.3369","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/79149-poly-adenosine-diphosphate-ribose-polymerase-parp-inhibitors-in-pancreatic-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:51Z","timestamp":1707507591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/79149-poly-adenosine-diphosphate-ribose-polymerase-parp-inhibitors-in-pancreatic-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.22575","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}